MINIMIZE RISK & UNCERTAINTY IN ONCOLOGY CLINICAL TRIALS

PROBLEM

LOW ONCOLOGY TRIAL PARTICIPATION

ONLY 3%
of oncology patients participate in clinical trials[1]

RISKS ARISE FROM AVOIDABLE ERRORS

77% wrong QTc data
Over/under-measures of site managed/paper ECGs = unnecessary withholding of treatment

Adverse event reporting QTc (increases) reported as adverse events

QTc DATA DETERMINES PATIENT INCLUSION/EXCLUSION

30-45% FALSE READINGS Most clinical trials set inclusion/exclusion and therapy hold/terminate criteria on QTc measures, but many oncologic agents prolong QTc

SITE¯MANAGED ECG ANALYSIS CAN NEGATIVELY IMPACT TRIALS

> Excludes eligible patients
> Extends recruiting
> Jeopardizes patient safety

SOLUTION

ECG CENTRALIZATION IN ONCOLOGY TRIALS LOWERS RISKS

ERT Cardiac Safety Solutions overcome ECG challenges and help to support enrollment, retention and safety goals.



Include more patients
30-45% patients who would be excluded from trials based on ECG machine measurements are actually eligible for inclusion

Withold fewer doses
Withholding medication based on ECG machine QTc measurements is actually unnecessary in most instances

APPROVE MORE POTENTIALLY LIFE¯SAVING MEDICATIONS

ECG centralization with ERT:

> Excludes fewer eligible patients
> Ensures patient safety
> Reduces study duration and costs

Review full study results at ert.com/CSoncology

[1] Marshall, MD, John L., Why Are Only 3% of US Cancer Patients in Clinical Trials? http://www.medscape.com/viewarticle/777662

ERT: PROVIDING CONFIDENCE AT EVERY TURN

PROVEN ONCOLOGY TRIAL EXPERIENCE

> **91** regulatory approvals across **1,076** oncology studies
> **35** oncology approvals within past **5** years
> **180,000+** cancer patients
> **25,000+** sites

DEEP ONCOLOGY TRIAL EXPERTISE

> Tailored solutions for Phase I & II trials
> Large-scale, global Phase III & IV expertise
> Oncology experience across most indications and complex therapies

KEEPING YOUR TRIALS ON TRACK AND ON BUDGET

> Reduce oncology site selection challenges, site burden and patient enrollment risks
> Improve oncology trial operations and efficiencies
> Enhance oncology data quality & increase outputs
> Reduce timelines and boost approval rates
> Provide the evidence you need to make your next move

SOLUTIONS FOR ALL YOUR TRIAL NEEDS

Enhance Trial Oversight | Enable Site Optimization | Improve Patient Engagement | Ensure Safety & Measure Efficacy

ERT®
Confidence at every turn™

@ERTglobal @ERTglobal

sales@ert.com | ert.com